Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study

Bønløkke, S E; Rand, Michael Schønemann; Haddock, Bryan; Arup, S; Smith, Christopher; Jensen, John; Schwarz, Peter; Hovind, Peter; Oturai, Peter; Jensen, Lars Thorbjørn; Möller, Sören; Eiken, Pia; Rubin, Katrine Hass; Hitz, Mette Friberg; Abrahamsen, Bo; Jørgensen, Niklas Rye

doi:10.1007/s00198-022-06457-0

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors have shown an association between high pretreatments levels of b-CTX-I and/or PINP and greater increases in BMD, reflecting the effectiveness of bisphosphonate therapy. However, this real-world study could not provide evidence that baseline BTMs can predict antifracture efficacy of osteoporosis therapies [18]. Therefore, BTMs are not currently part of the selection process for pharmacological treatment [6].…”

Section: Use In Osteoporosis Therapy Monitoringmentioning

confidence: 90%

“…Anabolic agents such as teriparatide and abaloparatide, two synthetic peptides of the parathyroid hormone family, are able to uncouple bone remodeling and induce an enhanced and rapid increase in bone formation [25,26]. Abaloparatide is designed to selectively bind R G -type PTHR1 and promote more transient signaling than PTH [1–34], resulting in a wider anabolic window [27]. A recent meta-analysis of eight randomized controlled trials showed that abaloparatide administration led to a significant enhancement in BMD at the lumbar spine, femoral neck and hip among postmenopausal women compared with the control group (placebo).…”

Section: Use Of Bone Turnover Markers In Osteoporosismentioning

confidence: 99%

See 1 more Smart Citation

Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis

Brouwers,

Bouquegneau,

Cavalier

2024

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of review Disturbances in mineral and bone metabolism occurring in osteoporosis and chronic kidney disease-associated osteoporosis place patients at high risk of fracture making these conditions a major public health concern. Due to the limited use of bone histomorphometry in clinical practice, the gold standard for assessing bone turnover, extensive efforts have been made to identify bone turnover markers (BTMs) as noninvasive surrogates. Since the identification of certain commonly used markers several decades ago, considerable experience has been acquired regarding their clinical utility in such bone disorders. Recent findings Mounting evidence suggested that BTMs represent a simple, low-risk, rapid and convenient way to obtain data on the skeletal health and that they may be useful in guiding therapeutic choices and monitoring the response to treatment. Summary BTMs could provide clinicians with useful information, independent from, and often complementary to bone mineral density (BMD) measurements. They have proven valuable for monitoring the effectiveness of osteoporosis therapy, as well as promising for discriminating low and high turnover states. Improved performance is observed when BTMs are combined, which may be useful for selecting treatments for chronic kidney disease-bone mineral disorders (CKD-MBD).

show abstract

Section: Use In Osteoporosis Therapy Monitoringmentioning

confidence: 90%

Section: Use Of Bone Turnover Markers In Osteoporosismentioning

confidence: 99%